Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
143M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
49.7M
-
Shares change
-
+4.47M
-
Total reported value, excl. options
-
$576M
-
Value change
-
+$50.4M
-
Put/Call ratio
-
0.06
-
Number of buys
-
55
-
Number of sells
-
-40
-
Price
-
$11.59
Significant Holders of Dyne Therapeutics, Inc. - Common Stock (DYN) as of Q4 2022
120 filings reported holding DYN - Dyne Therapeutics, Inc. - Common Stock as of Q4 2022.
Dyne Therapeutics, Inc. - Common Stock (DYN) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.7M shares
of 143M outstanding shares and own 34.87% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (9.87M shares), MPM ASSET MANAGEMENT LLC (4.95M shares), CITADEL ADVISORS LLC (2.91M shares), Deep Track Capital, LP (2.68M shares), BlackRock Inc. (2.62M shares), WASATCH ADVISORS INC (2.52M shares), EcoR1 Capital, LLC (2.32M shares), Vida Ventures Advisors, LLC (2.22M shares), Logos Global Management LP (2.15M shares), and FRANKLIN RESOURCES INC (1.78M shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.